Logo

American Heart Association

  45
  0


Final ID:

The Next Era in Cardiometabolic Treatment

  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Author Disclosures:
    Christie Ballantyne: DO have relevant financial relationships ; Researcher:merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Consultant:Arrowhead:Active (exists now) ; Researcher:Arrowhead:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Researcher:Ionis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Researcher:Eli Lilly:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Merck:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial.

Li Jianping, Zhou Zijian, Lv Lingchun, Gan Yulong, Wang Ying, Zhu Chaonan, Xu June, Huang Yanshan, Fang Yongliang, Zhang Long, Fan Yanting, Zhang Shu, Wang Liyun, Qu Yanling, Yin Guotian, Jiang Hongwei

Discussant

Lingvay Ildiko, Rosenson Robert

You have to be authorized to contact abstract author. Please, Login
Not Available